Newer anticoagulants for non-valvular atrial fibrillation.

Pharmaceuticals (Basel) · 2012 · PMC3763648 · PMID 24281558

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

did not reach statistical significancep = 0.051so close (0.05 < p ≤ 0.1)

There was a trend towards lower risk of death in the 150 mg dabigatran group versus the warfarin group, but this did not reach statistical significance (4.13% per year with warfarin versus 3.64% per year with 150 mg dabigatran, p = 0.051) [ 28 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.